

JOB OFFER		
REFERENCE	OPENING DATE	DEADLINE
2021.249	29/11/2024	08/12/2024
PROFILE REQUIREMENTS		
EXCLUSIVE REQUIREMENTS: (1)		
<b>ACADEMIC DEGREE</b>	Degree in Pharmacy/Equivalent (Justification must be provided with the application).	
VALUED MERITS / SKYLLS		
<b>FURTHER</b>	- Training in clinical trial data management - Training in handling and transport of dangerous goods (within the last 5 years).	
<b>EXPERIENCE</b>	- Previous experience in clinical trials	
<b>LANGUAGES</b>	-English (Certificates or diplomas must be provided).	
CONTRACT INFORMATION		
TYPE OF CONTRACT	EXPECTED INCORPORATION DATE	JOB STATUS
<b>Contract for scientific-technical activities</b> (article 23.bis of Law 14/2011, of June 1, on Science, Technology and Innovation)	<b>DECEMBER</b>	<b>Full time.</b> 1575 hours per year (aprox. 35 h/week)
ANNUAL GROSS SALARY	DURATION OF THE CONTRACT	
22.081,74 € without prejudice to the basic update established in state legislation for 2024.	<b>Indefinite</b> (linked to the duration of the project or to external financing or financing from public grants in full competition).	
WORK LOCATIONS	UNIT/DEPARTMENT	
<b>HUMV</b>	<b>REUMATOLOGY</b>	
JOB DETAILS		
OFFER DESCRIPTION		
Research support technician		
FUNCTIONS		
- SIDE-EFFECT MONITORING OF TRIAL MEDICATIONS - MEDICATION ASSISTANCE TO TRIAL SUBJECTS, CONTINUOUS TELEPHONE PAGING - ASSISTANCE WITH DRUG-DRUG INTERACTIONS OF TRIAL DRUGS		
PRINCIPAL INVESTIGATOR / RESPONSABLE	RESEARCH GROUP	RESEARCH PROJECT
<b>RICARDO BLANCO ALONSO</b>	<b>RESEARCH IN EPIDEMIOLOGY GENETICS AND ATHEROSCLEROSIS IN DISEASES INFLAMMATORY DISEASES AND IN DISEASES METABOLIC DISEASES OF THE BONE</b>	<b>2021.249 Phase 3, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of deucravacitinib in patients with active psoriatic arthritis (PsA) who are naïve to disease-modifying antirheumatic biologics or who have previously been treated with a TNF<math>\alpha</math> inhibitor.</b>
RECRUITMENT INFORMATION		
SELECTION PROCESS STAGES (2)		EMPLOYMENT EXCHANGE



<b>1. Admission of applications.</b> <b>2. Competition phase.</b> <b>3. Interview phase:</b> maximum number of candidates to be interviewed: 3. Minimum score for this phase: 30 <b>4. Report of the Tribunal.</b> <b>5. Resolution.</b>  <b>Note: in order for candidates to be considered for recruitment and employment exchange purposes, they must have a total score of at least 30 points.</b>				<b>NOT</b>
<b>SELECTION BOARD</b>				
<ul style="list-style-type: none"> <li>• <b>President:</b> Ricardo Blanco Alonso</li> <li>• <b>Member:</b> Francisco Galo Peralta</li> <li>• <b>Member and secretary:</b> Maria José Marín Vidalled</li> </ul>				
<b>VALUATION OF MERITS</b>				
MERITS	EVALUATION	SCORE		MAXIMUM
Training in clinical trial data management	Curricular	Merit fulfillment	YES/NO	20
Training in handling and transport of dangerous goods (within the last 5 years).	Curricular	Merit fulfillment	YES/NO	20
Previous clinical trial experience	Curricular	Merit fulfillment	YES/NO	10
English	Curricular	level	B1: 5 PTOS B2 OR MORE 10 PTOS	10
<b>FINAL SCORE</b>				
<b>MAXIMUM TOTAL SCORE BY MERITS</b>				<b>60</b>
<b>MAXIMUM TOTAL SCORE IN INTERVIEW</b>				<b>40</b>
<b>MAXIMUM TOTAL SCORE</b>				<b>100</b>

- (1) Not subsanable  
(2) See duration of each phase in the document "Selection Process"

*In compliance with the provisions of Article 11 of Organic Law 3/2018, you are informed that the person responsible for the processing of your personal data is the MARQUES DE VALDECILLA INSTITUTE OF INVESTIGATION FOUNDATION (IDIVAL), your data will be treated in order to be treated to the extent that they were necessary or convenient for the development of the legal relationship established between the parties. You can exercise your rights of access, rectification, deletion, opposition, portability or limitation of the treatment, by contacting the IDIVAL FOUNDATION at the following address: AVDA. CARDENAL HERRERA ORIA, S / N 39007, SANTANDER. More information at [www.idival.org/es/Política-de-Privacidad](http://www.idival.org/es/Política-de-Privacidad)*

Santander as of the date of electronic signature

Fdo. Francisco Galo Peralta Fernandez

